Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Biotech’s Bounce: Expecting Continued Strength

ph.investing.com/analysis/biotechs-bounce-expecting-continued-strength-117989
Biotech’s Bounce: Expecting Continued Strength
By Mike Zaccardi, CFA, CMT   |  Jun 29, 2022 17:21
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

This article was written exclusively for Investing.com

  • The speculative biotech industry endured its worst historical drawdown over the last 16 months
  • A recent thrust off long-term support creates a solid risk/reward setup for swing traders
  • Still, a bearish seasonal trend is a headwind for this high-risk space

Biotech stocks were among the hardest hit during the severe pullback in speculation that began in early 2021. While the S&P 500 notched an all-time high in early January this year, many other parts of the equity markets were already well into bear territory. The downtrend continued through the first half of 2022. The SPDR® S&P Biotech ETF (NYSE:XBI) went through its worst drawdown since its inception—more dramatic than what was seen during the 2008 Great Financial Crisis.

XBI Fell More than 60% Off Its 2021 High

SBI Daily
SBI Daily

Source: Koyfin Charts

Over the last year, XBI is off a whopping 44%, sharply underperforming the broad stock market and the Health Care sector. Investors can play the industry in another way, though. The iShares Biotechnology ETF (NASDAQ:IBB) is a cap-weighted product whereas XBI is equal-weighted. In essence, XBI is small/mid-cap and IBB is large-cap.

Both XBI and IBB are down big over the last 12 months as the sector ETF is positive

US Healthcare Sector
are Sector

Source: FinViz

But let’s dig into XBI. According to SSGA Funds, the ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index. XBI’s holdings are highly speculative. There are many niche drug manufacturers and therapeutic companies in the ETF. It’s a riskier vehicle to gain exposure to the biotech industry versus IBB.

SSGA reports that XBI’s price-to-earnings ratio is just 10.7 times next year’s forecast earnings. That’s incredibly cheap considering the sector’s P/E ratio is 15.6 times forward earnings, according to FactSet. The S&P 500’s next twelve-month earnings multiple is 15.8.

XBI Portfolio: Aggressive Constituents

Source: SSGA Funds

So “SMID” cap biotech stocks look inexpensive based on earnings. But how do the technicals shape up? I see bullish trends, but not all vital signs are positive in this health care area. Seasonality, for example, tends to turn somewhat bearish (on a relative basis vs the S&P 500) in July, according to Equity Clock. As a technician, I know that seasonality should always come second to what price says, so let’s move on to XBI’s chart.

Biotech’s Seasonal Trend vs the S&P 500: Typically Tops Out in Q3

Source: Equity Clock

The five-year weekly chart on XBI is interesting right now. The stock was up each day last week, bouncing off a key range in the low $60s. Moreover, the weekly candle was a bullish marubozu – when the opening prints near the low of the period while the closing print is the high. So, we have a key spot on the downside to watch, but what about levels to the upside?

I see two key spots to take profits. The first is of longer-term significance around $100 on the chart below. The next level has been important more recently—the $118 to $121 area was pivotal from 3Q 2020 through early 2022. Watch those points as you play XBI from the long side.

XBI 5-Year Weekly Chart: Defined Support and Resistance Levels

XBI 5-Year Weekly Chart
XBI 5-Year Weekly Chart

Source: Stockcharts.com

The Bottom Line

Biotech might be back. A strong thrust off long-term support on the equal-weight XBI ETF suggests more upside could be on the way. Traders should always seek defined risk/reward situations, and this fits that bill. A stop below the May low is prudent while gains should be harvested as the fund approaches $100.

Biotech’s Bounce: Expecting Continued Strength
 

Related Articles

Biotech’s Bounce: Expecting Continued Strength

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email